Your browser is no longer supported. Please, upgrade your browser.
IMGN ImmunoGen, Inc. monthly Stock Chart
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-0.43 Insider Own0.50% Shs Outstand174.35M Perf Week-1.34%
Market Cap687.20M Forward P/E- EPS next Y-0.75 Insider Trans-13.82% Shs Float173.22M Perf Month-15.87%
Income-70.30M PEG- EPS next Q-0.18 Inst Own80.50% Short Float9.35% Perf Quarter3.71%
Sales86.50M P/S7.94 EPS this Y41.80% Inst Trans0.91% Short Ratio7.05 Perf Half Y-10.88%
Book/sh-0.14 P/B- EPS next Y-8.70% ROA-26.60% Target Price6.96 Perf Year42.78%
Cash/sh1.30 P/C3.13 EPS next 5Y- ROE147.30% 52W Range1.95 - 7.07 Perf YTD-20.57%
Dividend- P/FCF- EPS past 5Y0.10% ROI124.60% 52W High-43.00% Beta2.27
Dividend %- Quick Ratio- Sales past 5Y-0.80% Gross Margin- 52W Low106.67% ATR0.26
Employees75 Current Ratio2.70 Sales Q/Q-3.20% Oper. Margin-59.70% RSI (14)43.01 Volatility5.33% 6.10%
OptionableYes Debt/Eq- EPS Q/Q52.50% Profit Margin-81.30% Rel Volume1.10 Prev Close4.05
ShortableYes LT Debt/Eq- EarningsJul 31 BMO Payout- Avg Volume2.30M Price4.03
Recom2.20 SMA20-6.14% SMA50-10.37% SMA200-3.67% Volume2,525,827 Change-0.62%
Dec-17-19Reiterated H.C. Wainwright Buy $5 → $9
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
May-15-19Downgrade Guggenheim Buy → Neutral
May-06-19Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19Upgrade Cowen Market Perform → Outperform
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $18 → $7
Feb-01-16Reiterated RBC Capital Mkts Outperform $19 → $18
Nov-25-15Upgrade Jefferies Hold → Buy
Sep-21-15Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-04-20 11:14AM  
Aug-03-20 04:30PM  
Jul-31-20 07:03PM  
Jul-29-20 04:30PM  
Jul-27-20 01:08PM  
Jul-24-20 12:30PM  
Jul-22-20 08:00AM  
Jul-20-20 07:00AM  
Jul-16-20 04:01PM  
Jul-14-20 05:31PM  
Jun-23-20 09:42PM  
Jun-22-20 09:01AM  
Jun-03-20 08:00AM  
Jun-02-20 08:00AM  
Jun-01-20 08:00AM  
May-31-20 11:30AM  
May-29-20 08:01AM  
May-20-20 10:04PM  
May-19-20 04:08PM  
May-15-20 12:01AM  
May-13-20 05:01PM  
May-06-20 04:30PM  
May-05-20 07:55AM  
May-04-20 04:17PM  
May-01-20 01:31PM  
Apr-24-20 12:30PM  
Apr-16-20 04:01PM  
Mar-15-20 11:30AM  
Feb-21-20 10:17AM  
Feb-18-20 08:35AM  
Feb-17-20 09:41AM  
Feb-14-20 05:00PM  
Feb-07-20 12:30PM  
Feb-06-20 04:30PM  
Feb-03-20 04:30PM  
Jan-30-20 04:01PM  
Jan-27-20 04:01PM  
Jan-23-20 07:24AM  
Jan-22-20 08:44PM  
Jan-03-20 10:46AM  
Dec-31-19 04:01PM  
Dec-24-19 07:12AM  
Dec-19-19 12:50PM  
Dec-18-19 08:25AM  
Dec-17-19 04:00PM  
Dec-14-19 09:13PM  
Dec-09-19 03:01PM  
Dec-01-19 09:30AM  
Nov-26-19 04:30PM  
Nov-18-19 09:34AM  
Nov-10-19 12:50AM  
Nov-07-19 02:51PM  
Nov-06-19 09:01AM  
Nov-05-19 07:29AM  
Nov-04-19 11:54AM  
Nov-01-19 07:45AM  
Oct-25-19 10:31AM  
Oct-18-19 04:30PM  
Sep-30-19 09:49AM  
Sep-29-19 06:01AM  
Sep-26-19 01:18PM  
Sep-17-19 06:30AM  
Sep-01-19 09:30AM  
Aug-07-19 11:20AM  
Aug-06-19 06:51AM  
Aug-05-19 10:18AM  
Aug-02-19 03:00PM  
Jul-26-19 10:30AM  
Jul-18-19 04:30PM  
Jul-12-19 08:58AM  
Jun-28-19 02:23PM  
Jun-27-19 11:21AM  
Jun-03-19 06:20PM  
Jun-02-19 09:30AM  
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOSTER DAVID GV.P.-Fin., Prin. Acctg. Off.Apr 02Sale3.435,44818,68721,382Apr 02 03:56 PM
Ryll ThomasSVP, Technical OperationsFeb 24Sale4.9916,79083,78275,624Feb 25 08:38 AM
Berkenblit AnnaSVP & Chief Medical OfficerFeb 24Sale4.9925,803128,75798,089Feb 25 08:37 AM
Enyedy Mark JChief Executive OfficerFeb 24Sale4.9955,222275,558433,776Feb 25 08:38 AM
BARROWS CRAIGExecutive VP, General CounselFeb 24Sale4.9916,49282,295145,275Feb 25 08:36 AM
Wingrove TheresaSVP of Regulatory AffairsFeb 24Sale4.9916,14780,57470,498Feb 25 08:37 AM